RBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $48
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $50 to $48.
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $50 to $48.